Top 10 most read GaBI Online articles in 2011

INICIO/Noticias Farmacéuticas | Posted 30/03/2012 post-comment

0 Post your comment

2011 was a busy year and biosimilars was the hot topic of the year for GaBI Online.

To ensure that none of GaBI Online’s readers have missed out on what happened in 2011, below is a list of the top 10 most read articles in 2011. Follow the links in the titles of each article to remind you what happened over the last year.

Article title and link*

EMA adopts guideline on biosimilar monoclonal antibodies

Market opportunities for biosimilars

Biosimilars approved in Europe

Development of biosimilars

Sandoz announces biosimilar rituximab

TNF biosimilar approved in China

The biggest US patent expiries of 2010

Brazil to manufacture biosimilar adalimumab

Challenges ahead for biosimilar development

Everybody jumping on the biosimilars bandwagon

*arranged in top 10 order with the most read article listed first

This shows that guidelines are the issues of most interest, followed by a general interest in news and current status around biosimilars development, for instance, opportunities, challenges and approval status around the globe (Brazil, China, Europe). Needless to say, scientific research data is one of the most popular articles within GaBI Online.

If you are interested in contributing a research article in a similar area to GaBI Journal, please send us your submission here.

GaBI’s mission – building trust in cost-effective treatments

Editor’s comment
What do you think about GaBI Online providing overviews of this type? Please feel free to share your thoughts via email or in the comments section below. What other overviews would you like to see?